Lamotrigine: A six-month, placebo-controlled, safety and tolerance study

Steven C. Schachter, Ilo E. Leppik, Fumisuke Matsuo, John A. Messenheimer, Edward Faught, Elizabeth L. Moore, Marc E. Risner

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


The safety of add-on lamotrigine (LTG, to 500 mg/day) was evaluated in 446 patients with partial seizures (334 LTG, 112 placebo) in a 6-month, multicenter, randomized, double-blind, parallel-group study. LTG had no clinically important effect on vital signs, electrocardiogram, body weight, clinical laboratory results, or physical and neurologic examination results. Dizziness, diplopia, ataxia, blurred vision, and somnolence occurred significantly more often with LTG treatment than with placebo. Most symptoms were mild or moderate and resolved with time. Eight percent of patients in both the LTG and placebo groups withdrew as a result of adverse events (AE). Three rashes in patients receiving LTG were judged serious by the investigators, and one, diagnosed as Stevens-Johnson syndrome, resulted in hospitalization; all resolved with discontinuation of LTG. Significantly more patients treated with LTG than with placebo improved as measured by the Investigators' Global Evaluations. LTG was well tolerated when administered as add-on treatment of epilepsy.

Original languageEnglish (US)
Pages (from-to)201-209
Number of pages9
JournalJournal of Epilepsy
Issue number3
StatePublished - Aug 1995

Bibliographical note

Funding Information:
Acknowledgment: This work was supported by Burroughs Wellcome, Research Triangle Park, NC, U.S.A. We thank the following individuals who contributed to the successful completion of this study: A. T. Dren, N. L. Earl, G. D. Rudd, H. H. Weissinger (all from Burroughs Wellcome); G. L. Barkley, Detroit, MI; D. Bergen, Chicago, IL; T. R. Browne III, Boston, MA; R. R. Carruthers, East Meadow, NY; C. M. DeGiorgio, Los Angeles, CA; M. E. Drake, Jr, Columbus, OH; F. E. Driefuss, Charlottesville, VA; F. W. Drislane, Boston, MA; A. L. Ehle, Chapel Hill, NC; D. F. Fleming, Greenville, NC; J. F. Foley, Salt Lake City, UT; B. B. Gal-lagher, Augusta, GA; R. N. Harner, Philadelphia, PA; P. W. Kaplan, Baltimore, MD; R. Kuzniecky, Birmingham, AL; K. D. Laxer, San Francisco, CA; R. F. Leroy, Dallas, TX; S. Louis, Providence, RI; J. S. Luther, San Antonio, TX; K. J. Oommen, Tucson, AZ; B. R. Parks, Jackson, MS; J. M. Pellock, Richmond, VA; S. H. Preskorn, Wichita, KS; R. A. Radtke, Durham, NC; R. C. Reed, Cleveland, OH; R. Ristanovic, Chicago, IL; W. E. Rosenfeld, St. Louis, MO; A. D. Rothner, Cleveland, OH; D. L. Schomer, Boston, MA; R. T. Simkins, Detroit, MI; D. B. Smith, Portland, OR; E. L. So, Marshfield, WI; T. R. Sunder, Greenville, NC; N. Sussman, Philadelphia, PA; T. M. Walshe, Brockton, MA; B. B. Wannamaker, Charleston, SC; L. A. Weis-berg, New Orleans, LA; and A. J. Wilensky, Seattle, WA, U.S.A.


  • Double-blind
  • Lamotrigine
  • Safety
  • Seizures
  • Stevens-Johnson
  • Tolerability


Dive into the research topics of 'Lamotrigine: A six-month, placebo-controlled, safety and tolerance study'. Together they form a unique fingerprint.

Cite this